These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 19207863

  • 1. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
    Li C, Gu Q.
    Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM, Brites FD, Fasulo V, Verona J, Elbert A, Wikinski RL, Schreier LE.
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [Abstract] [Full Text] [Related]

  • 5. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M, Karry R, Aviram M.
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.
    Circ Res; 2004 Oct 15; 95(8):789-97. PubMed ID: 15388641
    [Abstract] [Full Text] [Related]

  • 8. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
    Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS.
    Clin Sci (Lond); 2001 Dec 15; 101(6):659-70. PubMed ID: 11724654
    [Abstract] [Full Text] [Related]

  • 9. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
    Kalogerakis G, Baker AM, Christov S, Rowley KG, Dwyer K, Winterbourn C, Best JD, Jenkins AJ.
    Clin Sci (Lond); 2005 Jun 15; 108(6):497-506. PubMed ID: 15634192
    [Abstract] [Full Text] [Related]

  • 10. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities.
    Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M.
    J Agric Food Chem; 2008 Sep 24; 56(18):8704-13. PubMed ID: 18759451
    [Abstract] [Full Text] [Related]

  • 11. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
    Jornayvaz FR, Brulhart-Meynet MC, James RW.
    Nutr Metab Cardiovasc Dis; 2009 Nov 24; 19(9):613-9. PubMed ID: 19201174
    [Abstract] [Full Text] [Related]

  • 12. Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients.
    Fuhrman B, Volkova N, Aviram M.
    Nutrition; 2010 Apr 24; 26(4):359-66. PubMed ID: 19762215
    [Abstract] [Full Text] [Related]

  • 13. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K, Blazícek P, Waczulíková I, Zitnanová I, Duracková Z.
    Acta Biochim Pol; 2006 Apr 24; 53(4):783-7. PubMed ID: 17106515
    [Abstract] [Full Text] [Related]

  • 14. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.
    Mastorikou M, Mackness M, Mackness B.
    Diabetes; 2006 Nov 24; 55(11):3099-103. PubMed ID: 17065348
    [Abstract] [Full Text] [Related]

  • 15. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
    Cherki M, Berrougui H, Isabelle M, Cloutier M, Koumbadinga GA, Khalil A.
    Exp Gerontol; 2007 Aug 24; 42(8):815-24. PubMed ID: 17532162
    [Abstract] [Full Text] [Related]

  • 16. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
    Brites FD, Verona J, Schreier LE, Fruchart JC, Castro GR, Wikinski RL.
    Arch Med Res; 2004 Aug 24; 35(3):235-40. PubMed ID: 15163466
    [Abstract] [Full Text] [Related]

  • 17. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects.
    Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, Zeljkovic A, Stefanovic A, Zunic G.
    Eur J Clin Invest; 2007 Sep 24; 37(9):715-23. PubMed ID: 17696961
    [Abstract] [Full Text] [Related]

  • 18. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.
    Mastorikou M, Mackness B, Liu Y, Mackness M.
    Diabet Med; 2008 Sep 24; 25(9):1049-55. PubMed ID: 18937674
    [Abstract] [Full Text] [Related]

  • 19. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes.
    Sampson MJ, Braschi S, Willis G, Astley SB.
    Clin Sci (Lond); 2005 Aug 24; 109(2):189-97. PubMed ID: 15853770
    [Abstract] [Full Text] [Related]

  • 20. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes.
    Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K.
    Metabolism; 2000 Nov 24; 49(11):1400-5. PubMed ID: 11092501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.